Prevalence of clinical characteristics of patients with a (probable) Behçet*s syndrome in the Netherlands, a follow up cohort study.

Prevalence of clinical characteristics of patients with a (probable) Behçet*s syndrome in the Netherlands, a follow up cohort study. - Behcet study, longitudinal follow up

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45634

Enrollment

200

Registered

2017-07-13

Start date

2017-02-03

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet Syndrome Behcet's disease

Interventions

Behcet syndrome

immunology

observational study

questionnaires

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Adult patients who fullfill the international criteria of Behcet syndrome. Those with a clinical suspicion of Behcet syndrome.

Exclusion criteria

Exclusion criteria: none (except no informed consent)

Design outcomes

Primary

Measure	Time frame
No endpoints were defined, since it is an observational cohort study.	—

Secondary

Measure	Time frame
We wil record occurrence of disease manifestations and treatment given. Disease activity and QoL will be assessed using various questionnaires. We will measure NETosis by levels of circulating nucleosomes and systemic neutrophil activation will be assessed by released neutrophil elastase complex with its natural inhibitor alfa1-antitrypsine (ELA complexes) and levels of circulating nucleosomes. T cel regulation will be measured by clonal expansion.	—

Measure

Time frame

We wil record occurrence of disease manifestations and treatment given. Disease activity and QoL will be assessed using various questionnaires. We will measure NETosis by levels of circulating nucleosomes and systemic neutrophil activation will be assessed by released neutrophil elastase complex with its natural inhibitor alfa1-antitrypsine (ELA complexes) and levels of circulating nucleosomes. T cel regulation will be measured by clonal expansion.

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)